Elon Musk, the company’s chief executive, is fast losing out to Chinese electric carmakers in Tesla’s second-most-important market.

Elon Musk, the company’s chief executive, is fast losing out to Chinese electric carmakers in Tesla’s second-most-important market.

© Manaure Quintero/Agence France-Presse — Getty Images

The country’s top leaders set an optimistic growth target but gave few hints of how to achieve it as their export-led strategy is challenged by rising tariffs on Chinese goods.

In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies from importing goods into China.

China is still cautiously trying to figure out what Trump wants. The president has threatened big tariffs in response to the inaction.

Business owners told The Times that President Trump’s tariffs could lead to higher costs and expressed frustration at the sudden uncertainty about policy.

The development marked a breakthrough for Tesla’s chief executive, Elon Musk, in a country where his company has faced increasingly tough competition.

Asian countries are among the most vulnerable to President Trump’s economic grievances. But they are also best placed to make deals to minimize their exposure.

The once-sidelined Alibaba founder was among the executives who met with Xi Jinping, in what was seen as a show of support for private enterprise by Beijing.

The canal’s two biggest ports are operated by a Hong Kong company with global reach. The Trump administration sees a Chinese threat to U.S. security.

The little-known artificial intelligence firm has emphasized research, even as it emerged as the brainchild of a hedge fund.

China Vanke, one of the country’s largest developers, cleared out its top executives and said it anticipates a $6.2 billion loss, a sign the property meltdown is still raging.

Criticism over how the Chinese government buys drugs for its public health care system has ignited frustration over the quality of medicine.

Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.